Literature DB >> 24876731

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

Carlos Aguado1, Beatriz García-Paredes1, Miguel Jhonatan Sotelo1, Javier Sastre1, Eduardo Díaz-Rubio1.   

Abstract

Fluoropyrimidines play a central role in the first-line treatment of metastatic colorectal cancer. Our aim was to review whether capecitabine was a safer, non-inferior, economically superior and more convenient alternative to 5-fluorouracil. Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles. Furthermore, pharmacoeconomic data and patients' preferences for oral chemotherapy further favor capecitabine. Therefore, capecitabine appears to be an effective and safe alternative to fluorouracil in the first-line treatment of metastatic colorectal cancer.

Entities:  

Keywords:  5-Fluorouracil; Capecitabine; Metastatic colorectal cancer

Mesh：

Substances：

Year:  2014        PMID： 24876731      PMCID： PMC4033448          DOI： 10.3748/wjg.v20.i20.6092

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  49 in total

1.  First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

Authors:  Javier Sastre; Cristina Grávalos; Fernando Rivera; Bartomeu Massuti; Manuel Valladares-Ayerbes; Eugenio Marcuello; José L Manzano; Manuel Benavides; Manuel Hidalgo; Eduardo Díaz-Rubio; Enrique Aranda
Journal:  Oncologist       Date:  2012-02-23

2.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

3.  Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.

Authors:  J M Borras; A Sanchez-Hernandez; M Navarro; M Martinez; E Mendez; J L Ponton; J A Espinas; J R Germa
Journal:  BMJ       Date:  2001-04-07

4.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Authors:  Nicolas Moosmann; Ludwig Fischer von Weikersthal; Ursula Vehling-Kaiser; Martina Stauch; Holger G Hass; Herrmann Dietzfelbinger; Daniel Oruzio; Stefan Klein; Klaus Zellmann; Thomas Decker; Mathias Schulze; Wolfgang Abenhardt; Gerhard Puchtler; Herbert Kappauf; Johann Mittermüller; Christopher Haberl; Andreas Schalhorn; Andreas Jung; Sebastian Stintzing; Volker Heinemann
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

7.  Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Authors:  C-H Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; D Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; E Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem
Journal:  Ann Oncol       Date:  2007-12-06       Impact factor: 32.976

8.  Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Authors:  Eduardo Díaz-Rubio; Jose Tabernero; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Alberto Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

9.  A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

Authors:  Clemens Giessen; Ludwig Fischer von Weikersthal; Axel Hinke; Sebastian Stintzing; Frank Kullmann; Ursula Vehling-Kaiser; Julia Mayerle; Markus Bangerter; Claudio Denzlinger; Markus Sieber; Christian Teschendorf; Jens Freiberg-Richter; Christoph Schulz; Dominik Paul Modest; Nicolas Moosmann; Philipp Aubele; Volker Heinemann
Journal:  BMC Cancer       Date:  2011-08-23       Impact factor: 4.430

10.  Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

Authors:  J Souglakos; N Ziras; S Kakolyris; I Boukovinas; N Kentepozidis; P Makrantonakis; S Xynogalos; Ch Christophyllakis; Ch Kouroussis; L Vamvakas; V Georgoulias; A Polyzos
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640
View more
  8 in total

1.  Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis.

Authors:  Dan Zhang; Jiarui Wu; Kaihuan Wang; Xiaojiao Duan; Shi Liu; Bing Zhang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

2.  Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations.

Authors:  Majed Alshamrani; Atika AlHarbi; Nora Alkhudair; Fouad AlNajjar; Mansoor Khan; Abdulaziz Ben Obaid; Amr Khardaly; Eshtyag Bajnaid; Hadeel Samarkandi; Aeshah AlAzmi; Salman Alabdali; Mohammed AlNahedh
Journal:  J Oncol Pharm Pract       Date:  2020-06-24       Impact factor: 1.809

Review 3.  Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.

Authors:  Chengyi Mao; Xiaoxi Zeng; Chao Zhang; Yushang Yang; Xin Xiao; Siyuan Luan; Yonggang Zhang; Yong Yuan
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 4.  Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response.

Authors:  Yarden Ariav; James H Ch'ng; Heather R Christofk; Noga Ron-Harel; Ayelet Erez
Journal:  Sci Adv       Date:  2021-05-19       Impact factor: 14.136

5.  A 5-Fluorouracil-Induced Hyperammonemic Encephalopathy Challenged with Capecitabine.

Authors:  Michael Chahin; Nithya Krishnan; Hardik Chhatrala; Marwan Shaikh
Journal:  Case Rep Oncol Med       Date:  2020-01-31

Review 6.  Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine.

Authors:  William H Gmeiner
Journal:  Molecules       Date:  2020-07-29       Impact factor: 4.411

7.  An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities.

Authors:  Claire Palles; Susan Fotheringham; Laura Chegwidden; Marie Lucas; Rachel Kerr; Guy Mozolowski; Dan Rosmarin; Jenny C Taylor; Ian Tomlinson; David Kerr
Journal:  Cancers (Basel)       Date:  2021-03-24       Impact factor: 6.639

8.  Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.

Authors:  Xingqin Zhou; Yazhou Chang; Jing Qian; Chaoyan Shen; Jie Han; Hongyu Zhao; Renan Chang
Journal:  Med Sci Monit       Date:  2021-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.